DALLAS, Sept. 4, 2013 /PRNewswire-iReach/ -- Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics what generics are to branded drugs; they lower healthcare expenditures. The Biologics and Biosimilars World Markets ( http://www.rnrmarketresearch.com/biologics-and-biosimilars-world-markets-market-report.html ) report describes the emergence of biologics and biosimilars and their potential role in shaping the future of the global healthcare industry. The study analyzes the changing dynamics of the pharmaceutical market and provides insight into the regulatory pathways for branded pharmaceuticals and biologics, patent expirations, business strategies, clinical trials and drug applications. Key biologics and biosimilars are covered, including Humira (Adalimumab), Remicade (Infliximab), Lantus (Insulin Glargine), Levemir (Insulin Detemir), Privigen (Immune Globulin Intravenous), Aranesp (Darbepoetin Alfa), Enbrel (Etanercept), Herceptin (Trastuzumab) and Remicade (Infliximab). Moreover, this report examines companies that are actively developing and marketing biologics and biosimilars in the world. Detailed tables and charts with sales forecasts and marketshare data are also included.
Companies profiled in this report include 3Bio, Inc., Abbott Laboratories, AbbVie, Inc., Actelion Ltd., Amgen, Inc., Amoytop Biotech Co., Ltd, Anhui Anke Biotechnology (Group) Co., Ltd., Apotex, Inc., Astellas Pharma, Inc., AstraZeneca, Bayer, Beijing Four Rings Biopharmaceuticals, Bharat Serums and Vaccines Limited, Biocon Ltd., Biogen Idec, Inc., Bioton SA, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Co., Celgene Corporation, Celltrion, Inc., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Elan Corporation, PLC, Eli Lilly & Co., Gideon Richter, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hospira, Inc., Intas Pharmaceuticals Limited, Johnson & Johnson, Merck & Co., Inc., Mylan, Inc., Novartis AG, Pfizer, Inc., Roche Holdings AG, Sandoz International GmbH, Sanofi, Stada Arzneimittel Aktiengesellschaft, Teva Pharmaceutical Industries Limited and Watson Pharmaceuticals, Inc.
Bioseparations systems can be categorized into three types: chromatography, membranes/filters and centrifuges. The demand for single use products is increasing and fueling growth of the global bioseparations market. New biosimilars are driving the increase in global biomanufacturing capacity. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. The Bioseparation Systems for Global Biopharmaceutical Markets ( http://www.rnrmarketresearch.com/bioseparation-systems-for-global-biopharmaceutical-markets-market-report.html ) report provides market revenue size and growth rates for North America, Europe, Asia-Pacific (Japan, South Korea, Singapore) and the emerging BRICs (Brazil, Russia, India, China). Single-use products, manufacturing capacity, applications of bioseparations in downstream processing, downstream processing bottlenecks and emerging bioseparations technologies are covered in detail. The report also analyzes the competitive landscape, including key playersõ strengths and weaknesses, opportunities, gaps and industry trends. Detailed tables and charts with sales forecasts and marketshare data are also included.
The competitive landscape section of this report covers information on Strategy, Bioseparations Product Mix and Brands, Platforms and Product Groups, Process Development and Technical Support as well as New product launches for companies like GE Healthcare Life Sciences, Merck Millipore, Pall Corporation, Sartorius and 3M CUNO. Additionally, the company profiles mentioned in this report provide data and information for Agilent Technologies, Alfa Wassermann Separation Technologies, Applied Biosystems Corporation (Life Technologies), Asahi Kasei, Bio-Rad Laboratories, Carr Centritech, Celeros, Dow Chemical Company, DSM Biologics, Flottweg Separations Technology, G-Con Manufacturing, GEA Westfalia Separator Group, GE Healthcare Life Sciences, Hitachi Koki Co. LTD, Knauer, Kronlab (YMC Europe), Life Technologies, Meissner Filtration Products, Inc., Merck Millipore, 3M Cuno, Novasep Life Sciences Manufacturing Solutions, Novavax, NuSep Holdings Ltd, Pall Corporation, ProMetic Life Sciences Inc., Sartorius Stedim Biotech, SciLog, Spectrum Laboratories, Tarpon Biosystems, Tosoh Bioscience, U.S. Filter Control Systems, Inc. and Waters Corporation.
Explore more reports on Biosimilars at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/biosimilar and on Biopharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology/biopharmaceutical .
RnRMarketResearch.com ( http://www.rnrmarketresearch.com/ ) is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. Call +1 888 391 5441 with your research requirements.
Media Contact: Priyank Tiwari, RnR Market Research, +1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research